Tuesday, April 22, 2025

Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development

Related stories

Duda Launches AI Tool to Revolutionize Content Collection

Leading website builder for agencies, Duda, launches an innovative...

Beghou Names AI Leader Pradeepta Mishra as VP, AI Innovation

Pradeepta Mishra’s deep technical expertise and leadership to help...

NowVertical Launches DataCatalyst on Microsoft Azure Marketplace

NowVertical Group Inc., a leading data and AI solutions...

Russ Johannesson Named CEO of Caregentic to Drive Growth

Strategic leadership appointment positions Caregentic to lead next wave...

ViQi & Araceli partner on AI phenotypic cell assay profiling

ViQi and Araceli Biosciences collaborated to integrate ViQi's AI-powered...
spot_imgspot_img

Caris Discovery, the therapeutic research arm of Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer, announced a multi-year strategic partnership with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to accelerate the discovery and development of first-in-class antibody-drug conjugates (ADC) for cancer patients.

“We are thrilled to join forces with Merck KGaA, Darmstadt, Germany, to discover targets with the first-in-class potential to advance the next wave of transformational ADC therapeutics,” said Brian Lamon, PhD, Chief Business Officer of Caris. “This partnership adds to our portfolio of external pipeline programs and is a strong validation of our highly differentiated, orthogonal multi-omics approach to discovering truly novel targets that may be harnessed to eradicate tumors.”

Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Caris with an upfront payment as well as research funding. In addition, Caris will be eligible for discovery, development, regulatory and sales-based milestone payments that may total up to $1.4 billion along with tiered royalties. Merck KGaA, Darmstadt, Germany will receive an exclusive global license to develop, manufacture and commercialize ADC therapeutics for selected targets.

Also Read: Aurigene Pharmaceutical Services Ltd. introduces Aurigene.AI™, an artificial intelligence (AI) and machine learning (ML) assisted drug discovery platform

“We are dedicated to addressing high unmet needs across multiple cancer types,” said Paul Lyne, Global Head of Research Unit Oncology for the Healthcare business sector of Merck KGaA, Darmstadt, Germany. “Through close collaboration with Caris, utilizing their unique discovery platform, we complement our internal ADC capabilities to develop novel first-in-class ADCs and ultimately strengthen our potential to expand our oncology portfolio.”

Caris Discovery leverages the scale of Caris’ core molecular profiling business to discover novel, druggable targets that would be otherwise inaccessible through more traditional approaches. Through the convergence of its proprietary ADAPT Biotargeting platform, a contemporaneous patient tissue repository, a suite of sophisticated AI and machine learning capabilities, and its dedicated 59,000 square foot discovery research laboratory, Caris Discovery aims to identify and validate new therapeutic targets that can be harnessed by its biopharma partners to develop the next generation of oncology therapies. Under this partnership, targets discovered and validated by Caris can be pursued by Merck KGaA, Darmstadt, Germany. Merck KGaA, Darmstadt, Germany will be responsible for the preclinical and clinical research, as well as the development and commercialization of drug candidates emanating from these programs.

“Caris Discovery is uncovering novel unexplored targets in patient populations where precision therapeutics have yet to be developed,” said Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris. “We are proud to be working closely with Merck KGaA, Darmstadt, Germany, to bring new therapeutic options to cancer patients together.”

SOURCE: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img